BioRestorative Therapies, Inc. is a life sciences company, which is focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. It offers two developmental programs, namely Disc/Spine Program (brtxDisc) and Metabolic Program (ThermoStem), which relate to the treatment of disc/spinedisease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous hypoxic cultured mesenchymal stem cell (MSC) product derived from a patient’s own bone marrow and formulated with a biomaterial carrier (platelet lysate). BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. It is engaged in developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC), to generate brown adipose tissue (BAT).